The Development of Immunotherapies to Treat Lymphoma
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (31 March 2026) | Viewed by 2889
Special Issue Editor
Special Issue Information
Dear Colleagues,
We are pleased to announce a call for submissions for a Special Issue of Cancers, entitled “The Development of Immunotherapies to Treat Lymphoma”. Lymphoma, a diverse group of hematologic malignancies, has seen significant therapeutic advances in recent years, particularly with the advent of immunotherapy.
This Special Issue aims to explore the latest research and clinical developments in the field of immunotherapy for lymphoma. We invite researchers to submit original articles and comprehensive reviews addressing all aspects of immunotherapeutic strategies, including, but not limited to, the following:
- Mechanisms of immune evasion and immune system interactions in lymphoma.
- Development and clinical application of monoclonal antibodies.
- Chimeric antigen receptor (CAR) T-cell therapies and bispecific T-cell engagers.
- Immune checkpoint inhibitors and their role in lymphoma treatment.
- Combination therapies and personalized approaches to immunotherapy.
- Challenges and opportunities in translating immunotherapies from bench to bedside.
All submitted manuscripts will undergo a rigorous peer-review process to ensure the highest scientific quality and relevance to the field. We welcome contributions from researchers, clinicians, and industry experts working to advance the field of lymphoma pathogenesis and treatment.
By consolidating the latest findings and innovative approaches, this Special Issue aims to deepen our understanding of lymphoma immunobiology and to promote the development of novel immunotherapies. We believe that your valuable insights will significantly contribute to the success of the Special Issue.
For any inquiries or further information, please feel free to contact us. We are committed to supporting your participation in this Special Issue.
Thank you for your attention, and we eagerly anticipate your submissions.
Dr. Christina Kalpadakis
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lymphoma immunotherapy
- CAR T-cell therapy
- immune checkpoint inhibitors
- monoclonal antibodies
- personalized immunotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
